Abstract-The authentic standards GSK1482160 and its isomer, as well as the radiolabeling precursors desmethyl-GSK1482160 and Boc-protected desmethyl-GSK1482160 were synthesized from L-pyroglutamic acid, methyl L-pyroglutamate and 2-chloro-3-(trifluoromethyl)benzylamine with overall chemical yield 27-28% in 3 steps, 58% in 4 steps, 76% in 1 step and 33% in 2 steps, respectively. [
The purinergic receptor P2X ligand-gated ion chanel type 7 (P2X 7 receptor) is an adenosine triphosphate (ATP)-gated ion-channel. It is found in the immune, peripheral, and central nervous systems; implicated in ATP-mediated cell death, regulation of receptor trafficking and inflammation; and associated with various cancer, neurological and cardiovascular disorders. [1] [2] [3] [4] Neuroinflammation is considered to play an important role in a variety of neuropathologies, such as Alzheimer's disease, Parkinson's disease and traumatic brain injury. [5] [6] [7] P2X 7 receptor antagonists have been developed as potential pharmaceuticals for the treatment of various diseases including neuroinflammation. [8] [9] [10] We are interested in biomedical imaging to detect and quantify neuroinflammation, with positron emission tomography (PET) offering the best opportunity for success with development and validation of suitable targeted radioligands. However, an ideal PET radiopharmaceutical is still missing. 11, 12 Like others, we have used [ 11 C]PBR28-PET (Figure 1 ) to image neuroinflammation, targeting the 18-kDa translocator protein (TSPO) formerly named the peripheral benzodiazepine receptor (PBR). 13, 14 However, the limitations 15, 16 of [ 11 C]PBR28-PET such as low receptor binding, high inter-subject variability in binding affinity, and nonspecific binding in the human brain, due to TSPO polymorphism, have motivated us to search for new molecular targets and PET radioligands.
Increasing evidence suggests the P2X 7 receptor as an interesting neuroinflammation-associated molecular target. 12, 17 Recently the synthesis and initial preclinical evaluation of a P2X 7 receptor radioligand [ 11 C]A-740003 (racemic compounds, Figure 1 ) have been reported, but it showed little uptake in brain in healthy male Wistar rats. 12 We have instead initially focused on GSK1482160 (a chiral compound, (S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-1-methyl-5-oxopyrrolidine-2-carboxamide, 3). Originally developed by GlaxoSmithKline, GSK1482160 is a potent P2X 7 antagonist with excellent biological activity {PIC 50 8.5 (IC 50 3 nM) for human P2X 7 , and PIC 50 6.6 for rat P2X 7 }. [18] [19] [20] This compound readily crosses the bloodbrain barrier (BBB), and has been evaluated as a therapeutic agent in a Phase 1 human study, [18] [19] [20] making it an attractive candidate for possible translation to a PET diagnostic agent.
Here we report the synthesis of
11 C]3} as a new candidate PET agent for imaging of P2X 7 receptor. The reference standard GSK1482160 was synthesized as shown in Scheme 1.
18,19
L-Pyroglutamic acid or methyl L-pyroglutamate was reacted with methyl iodide (CH 3 I) and NaH in N,N-dimethylformamide (DMF) to convert into methyl (S)-1-methyl-5-oxopyrrolidine-2-carboxylate (1) in 41-43% yield. Subsequently, compound 1 was de-esterified with NaOH to give (S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid (2) in 82% yield. Then compound 2 underwent a coupling reaction with 2-chloro-3-(trifluoromethyl)benzylamine, using 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) or 1-ethyl-3-(3-dimethylaminopropyl)carbodimide (EDAC) as catalyst, affording standard compound 3 in 80% yield. The radiolabeling precursors desmethyl-GSK1482160 {(S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-carboxamide, 4} and Boc-protected desmethyl-GSK1482160 (tert-butyl (S)-(2-chloro-3-(trifluoromethyl)benzyl)(5-oxopyrrolidine-2-carbonyl)carbamate, 5), were synthesized as indicated in Scheme 2. The precursor desmethyl-GSK1482160 was prepared from L-pyroglutamic acid and 2-chloro-3-(trifluoromethyl)benzylamine, with EDAC and 1-hydrobenzotrizole (HOBt) as catalysts, 21 in 76% yield. The alternative radiochemistry precursor, Boc-protected desmethyl-GSK1482160, was prepared from desmethyl-GSK1482160 with di-tert-butyl-dicarbonate {(Boc) 2 O} using base catalyst 4-dimethylaminopyridine (DMAP) 22 in acetonitrile in 44% yield. As a reference compound, the GSK1482160 isomer (S)-N- (2-chloro-3-(trifluoromethyl) benzyl)-N-methyl-5-oxopyrrolidine-2-carboxamide (9) was synthesized as outlined in Scheme 3.
2-Chloro-3-(trifluoromethyl)benzylamine was reacted with (Boc) 2 O in THF and water (1:1) without catalyst to give Bocprotected tert-butyl (2-chloro-3-(trifluoromethyl)benzyl)carbamate (6) in 90% yield. Subsequently compound 6 was methylated with CH 3 I and NaH to afford tert-butyl (2-chloro-3-(trifluoromethyl)benzyl)(methyl)carbamate (7) in 91% yield. Compound 7 was deprotected with trifluoroacetic acid (TFA) in CH 2 Cl 2 to obtain 1-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylmethanamine (8) in 91% yield. Then compound 8 was reacted with Lpyroglutamic acid using similar synthetic method for standard compound 3 to produce GSK1482160 isomer in 78% yield. The 1 H NMR spectra of compound 9 showed it contained two epimers, since the methyl group is located at the side chain amide. This steric factor does not apply to compound 5. Compound 9 was formed by the coupling reaction from two different reaction directions, which gave two epimers. The reaction mechanism for synthesis of compound 5 is the substitution reaction of amide; in addition, Boc is a bulky group, thus compound 5 was formed through a preferential reaction direction, and no epimers were seen in its 1 H NMR spectra. 27, 28 in acetonitrile at 80 °C under basic conditions (NaH) The product was isolated by semipreparative reverse-phase (RP) high performance liquid chromatography (HPLC) with a C-18 column, and then concentrated by solid-phase extraction (SPE) with a disposable C-18 Plus Sep-Pak cartridge [29] [30] [31] to produce the corresponding pure radiolabeled compound [
11 C]3 in 40-50% radiochemical yield, decay corrected to end of bombardment (EOB), based on [
11 C]CO 2 . This is a 1-pot-1-step radiosynthesis.
The desmethyl-GSK1482160 precursor contains both cyclic amide and side chain amide. Although the cyclic amide is more easily deprotonated and methylated than side chain amide, a minor by-product
) was formed as well. The [
11 C]GSK1482160 and [ 11 C]GSK1482160 isomer were formed in a ~10:1 ratio from desmethyl-GSK1482160. Different solid bases, such as NaOH, KOH, K 2 CO 3 , Cs 2 CO 3 and NaH, were tested in the radiolabeling reaction, and NaH proved to be the best base for the N-[
11 C]methylation of cyclic amide. 11 C]GSK1482160. This was followed by a quick deprotection reaction with 1 M HCl, without isolation, to provide the target tracer. The radiolabeling mixture was isolated by RP-HPLC combined with SPE to produce the corresponding pure radiolabeled compound [ 11 C]3 in 30-40% decaycorrected radiochemical yield. This is a 1-pot-2-step radiosynthesis. 22 The best base for the radiolabeling reaction was freshly ground K 2 CO 3 powder. 25 For the Boc-protected desmethyl-GSK1482160 precursor, it was better to conduct the N-[ 11 C]methylation of amide under mildly basic conditions (K 2 CO 3 ), since the Boc protecting group is not very stable under strongly basic conditions with high reaction temperature. Only a relatively small amount of the precursor (0.3-0.5 mg) was used for radiolabeling, instead of our more commonly used amount of the precursor (1.0-1.5 mg), which improved the chemical purity of the final tracer solution. Furthermore, addition of NaHCO 3 solution to quench the radiolabeling reaction and to dilute the radiolabeling mixture prior to the injection onto the semi-preparative HPLC column for purification, gave better separation of [ 11 C]3 from its unprotected or protected amide precursor (4 or 5). [29] [30] [31] 33 The radiosynthesis was performed in a home-built automated multi-purpose [
11 C]-radiosynthesis module. [34] [35] [36] This radiosynthesis module facilitated the overall design of the reaction, purification and reformulation capabilities in a fashion suitable for adaptation to preparation of human doses. In addition, the module is designed to allow in-process measurement of [ 11 C]-tracer specific activity (SA, GBq/mol at EOB) using a radiation detector at the outlet of the HPLCportion of the system. 26 For the reported syntheses, product SA was in a range of 370-1110 GBq/mol at EOB.
The factors that affect the EOB SA significantly to lead to such a wide range from 370 to 1110 GBq/mol are mainly from two parts: (1) The 1-pot-1-step radiosynthesis via desmethyl-GSK1482160 is a non-specific synthesis route, and 1-pot-2-step radiosynthesis via Boc-protected desmethyl-GSK1482160 is a specific synthesis route. The nonspecific route required lower reaction temperature, shorter reaction time, and shorter overall synthesis time.
Consequently it gave higher radiochemical yield. In addition, it is easier to synthesize the precursor without Boc group than with Boc group. This route is somewhat simpler to implement as it avoids adding a deprotection step. Fortunately, this route proceeds with high selectivity (~10:1) for [ 11 C]methylation at the N of the desired cyclic amide over the acyclic amide, and the desired product has been cleanly isolated after semipreparative HPLC purification of the radiolabeling reaction mixture. In comparison with these two radiosynthesis approaches, the non-specific route is identified as a more appropriate route for future applications.
Chemical purity and radiochemical purity were determined by analytical HPLC. 37 The chemical purity of the precursors and reference standards was >93%. The radiochemical purity of the target tracers was >99% determined by radio-HPLC through -ray (PIN diode) flow detector, and the chemical purity of the target tracers was >90% determined by reversed-phase HPLC through UV flow detector.
The experimental details and characterization data for compounds 1-9 and for the tracer [ 11 C]3 are given. 38 In summary, synthetic routes with moderate to excellent yields have been developed to produce the precursors desmethyl-GSK1482160 and Boc-protected desmethyl-GSK1482160; the reference standards GSK1482160 and GSK1482160 isomer; and the target PET radiotracer [ 11 28 Melting points were determined on a MEL-TEMP II capillary tube apparatus and were uncorrected.
1 H NMR and 13 C NMR spectra were recorded at 500 and 125 MHz, respectively, on a Bruker Avance II 500 MHz NMR spectrometer using tetramethylsilane (TMS) as an internal standard. Chemical shift data for the proton resonances were reported in parts per million (ppm,  scale) relative to internal standard TMS ( 0.0), and coupling constants (J) were reported in hertz (Hz). Liquid chromatography-mass spectra (LC-MS) analysis was performed on an Agilent system, consisting of an 1100 series HPLC connected to a diode array detector and a 1946D mass spectrometer configured for positiveion/negative-ion electrospray ionization. The high resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT Classic spectrometer. Chromatographic solvent proportions are indicated as volume:volume ratio. Thin-layer chromatography (TLC) was run using Analtech silica gel GF uniplates (5  10 cm 2 ). Plates were visualized under UV light. Normal phase flash column chromatography was carried out on EM Science silica gel 60 (230-400 mesh) with a forced flow of the indicated solvent system in the proportions described below. All moisture-and air-sensitive reactions were performed under a positive pressure of nitrogen maintained by a direct line from a nitrogen source. Analytical HPLC was performed using a Prodigy (Phenomenex) 5 m C-18 column, 4.6  250 mm; mobile phase 40% CH 3 CN/60% 20 mM H 3 PO 4 ; flow rate 1.0 mL/min; and UV (254 nm) and -ray (PIN diode) flow detectors. Semi-preparative HPLC was performed using a Prodigy (Phenomenex) 5 m C-18 column, 12 nm, 10  250 mm; mobile phase 40% CH 3 CN/60% H 2 O; 5.0 mL/min flow rate; UV (254 nm) and -ray (PIN diode) flow detectors. C18 Plus Sep-Pak cartridges were obtained from Waters Corporation (Milford, MA). Sterile Millex-FG 0.2 m filter units were obtained from Millipore Corporation (Bedford, MA).
To a stirred suspension of sodium hydride (60% dispersion in mineral oil, 2.1 g, 52 mmol) in DMF (60 mL) at 0 °C under nitrogen, L-pyroglutamic acid (2.58 g, 20 mmol) was added during 15 min. The mixture was stirred at room temperature (RT) for 1 h. While ice cooling and stirring, iodomethane (7.76 g, 55 mmol) was added and the reaction mixture was allowed to warm to RT overnight. The solvent was evaporated under reduced pressure, and water was added. After pH was adjust to 5 with adding acetic acid, the aqueous layer was extracted with CH 2 Cl 2 (100 mL × 3). The organic layer was concentrated, and the residue was purified by column chromatography on silica gel with eluent (30:70 EtOAc/hexanes) to give colorless oily product 1 (1.35 g, 43%). R f = 0.68 (1:19 MeOH/CH 2 Cl 2 ). Methyl Lpyroglutamate (1.43 g, 10 mmol was dissolved in DMF (25 mL) and cooled to 0 °C. Sodium hydride (60% suspension in mineral oil, 0.6 g, 15 mmol) was added to the reaction mixture and stirred for 1 h. Then methyl iodide (2.11 g, 15 mmol) was added slowly, the mixture was allowed to warm to RT and stirred for another 1 h. The solvent was evaporated in vacuo, and water was added, subsequently acetic acid was added to adjust pH to 5, the aqueous layer was then extracted with CH 2 Cl 2 (60 mL × 3). The organic layer was concentrated, and the residue was purified by column chromatography on silica gel with eluent (30:70 EtOAc/hexanes) to yield colorless oily product 1 (0.64 g, 41%). Analytical data was identical with Method A. (2) : Compound 1 (0.47 g, 3.0 mmol) was dissolved in methanol (20 mL), and to this solution was added 2 M NaOH (3 mL, 6.0 mmol). The mixture was refluxed for 3 h, then cooled and evaporated to leave a minimal amount of water. This mixture was acidified to pH 2 using 1 M aqueous HCl. The aqueous was extracted with CH 2 Cl 2 (100 mL × 3), and organic layer was washed with water, dried over MgSO 4 (6) : 2-Chloro-3-(trifluoromethyl)benzylamine (210 mg, 1.0 mmol) was dissolved in THF-water (1:1) and then (Boc) 2 O (229 mg, 1.05 mmol) was added to the solution. The reaction mixture was stirred at RT for overnight. Then the mixture was concentrated in vacuo, and cooled down. The resulting precipitate was filtered, washed with water, and dried, affording white solid product 6 (278 mg, 90%). R f = 0.60 (1:5 EtOAc/hexanes), mp 98-100 °C.
(c) (S)-1-Methyl-5-oxopyrrolidine-2-carboxylic acid

